An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
VERDICT
The label
Accumulation
read at $31.49
Catalyst Pharmaceuticals, Inc. holds its Accumulation at $31.49.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 214 days
Price
$31.49
Valuation
18.20 trailing · 9.05 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.74
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$31.49
18.20 P/E · 9.05 fwd
Our fair value
$32.00
2% discount
Analyst target (avg)
$31.50
+0% to current
Target low $31.50Analyst target rangeTarget high $32.00
▲ current $31.49 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$31.49
you are here
Conservative
$32.00
+2%
Analyst avg
$31.50
+0%
Our fair value
$32.00
+2%
Analyst high
$32.00
+2%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
Revenue growth
5.60%
Profit margin
37.08%
Debt to equity
0.27
Analyst consensus
None · 3 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare Disease Drugmaker Offers Little Margin Of Safety
Picture a patient in the US finally getting reliable access to treatment for a muscle disorder that most doctors barely know. Catalyst Pharmaceuticals turns that need into a commercial product with 37% profit margins and 24% return on equity. Yet the shares sit just 2% below our fair value estimate, which is why the opportunity rating stays at none despite clearing the ethical screen.
The business trades on a forward multiple of 9 times earnings with only 6% revenue growth expected. Three analysts see a median target at the current price level, so the low multiple simply reflects modest expansion rather than a bargain. An unknown competitive moat leaves the durability of those margins open to question once any new rivals appear.
Biotech remains exposed to regulatory shifts and single-product concentration even in rare-disease niches. With growth this contained and the valuation already matched to fair value, the setup carries no real edge. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CPRX trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33. Entered 2026-07-25 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-25Accumulation$31.49+0.4%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-07-18Accumulation$31.36+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (5 analysts) rates it none, with a mean price target of $33.
2026-07-03Accumulation$31.36+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$31.36Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$31.15
+0.6%
·
$1,006
+0.6%
2 months
$24.94
+25.7%
·
$1,257
+25.7%
3 months
$23.39
+34.0%
·
$1,340
+34.0%
6 months
$22.94
+36.6%
·
$1,366
+36.6%
1 year
$26.31
+19.1%
·
$1,191
+19.1%
2 years
$15.63
+100.5%
·
$2,005
+100.5%
3 years
$11.62
+169.7%
·
$2,697
+169.7%
5 years
$5.74
+446.0%
·
$5,460
+446.0%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever CPRX does next, these words stay.
Catalyst Pharmaceuticals, Inc. · CPRX · Accumulation · $31.49
Recorded 2026-07-19 · before the outcome · scored mechanically
